Lm-LLO-Based Immunotherapies and HPV-Associated Disease

Table 2

Lm-LLO-based immunotherapy increases CD8⁺ T cells (TILs) and decreases CD25⁺CD4⁺FoxP3⁺ Tregs in tumor. Comparison of CD8⁺ T cells (TILs) and CD25⁺CD4⁺FoxP3⁺ Tregs in TC1 mouse tumor after treatment with Lm-E7 or Lm-LLO-E7. The data has been adopted and modified from Shahabi et al. [17].

Immunotherapy group	E7/Db tetramer positive activated CD8^+ T cells in tumors (TILs)	CD25^+CD4^+FoxP3^+ Tregs in the tumor	CD8^+ TIL : Tregs ratio
Lm-E7	9.4%	11.8%	0.80
Lm-LLO-E7	36.8%	1.7%	21.65